CD8 Antibody (12.C7)

Novus Biologicals, part of Bio-Techne | Catalog # NB100-64021

Novus Biologicals, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
NB100-64021
NB100-64021-0.025mg
Print Quote
Bulk Order
100% Guarantee

Key Product Details

Validated by

Biological Validation

Species Reactivity

Validated:

Rabbit

Cited:

Rabbit

Applications

Validated:

Flow Cytometry, Immunocytochemistry/ Immunofluorescence, Immunohistochemistry, Immunohistochemistry-Paraffin

Cited:

Flow Cytometry, IF/IHC, Immunocytochemistry/ Immunofluorescence, Immunohistochemistry-Paraffin

Label

Unconjugated

Antibody Source

Monoclonal Mouse IgG1 Clone # 12.C7

Concentration

1.0 mg/ml

View all CD8 Antibodies »

Product Specifications

Immunogen

CD8 Antibody (12.C7) was developed against Rabbit CD8

Specificity

CD8 Antibody (12.C7) recognizes the rabbit CD8 cell surface antigen, expressed by a subset of T lymphocytes with cytotoxic/suppressor activity.

Clonality

Monoclonal

Host

Mouse

Isotype

IgG1

Theoretical MW

26 kDa.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.

Scientific Data Images for CD8 Antibody (12.C7)

Immunohistochemistry: CD8 Antibody (12.C7) - BSA Free [NB100-64021]

Immunohistochemistry: CD8 Antibody (12.C7) - BSA Free [NB100-64021]

Immunohistochemistry: CD8 Antibody (12.C7) [NB100-64021] - scAAV8G9-optHLA-G Combo Prevents Cornea Burn-induced Vascularization and Cytotoxic T-cell Infiltration. Rabbit cornea sections were acquired 60 days following the injection of indicated vectors into burn corneas and stained for an endothelial cell marker (CD31), T cell markers, transgene abundance, and a-SMA in the indicated treatment groups. Scale bars=5um. Image collected and cropped by CiteAb from the following publication (nature.com/articles/s41598-017-18002-9), licensed under a CC-BY license.
Immunohistochemistry-Paraffin: CD8 Antibody (12.C7) - BSA Free [NB100-64021]

Immunohistochemistry-Paraffin: CD8 Antibody (12.C7) - BSA Free [NB100-64021]

Immunohistochemistry-Paraffin: CD8 Antibody (12.C7) [NB100-64021] - Human bile duct cancer tissue. IHC-P image submitted by a verified customer review.
Flow Cytometry: CD8 Antibody (12.C7) - BSA Free [NB100-64021]

Flow Cytometry: CD8 Antibody (12.C7) - BSA Free [NB100-64021]

Flow Cytometry: CD8 alpha Antibody (12.C7) [NB100-64021] - Rabbit peripheral blood lymphocytes stained with Mouse anti Rabbit CD8 Alpha followed by Goat anti Mouse IgG (H/L):FITC
View 1 more images

Applications for CD8 Antibody (12.C7)

Application
Recommended Usage

Flow Cytometry

1:100-1:200

Immunocytochemistry/ Immunofluorescence

1:10-1:500

Immunohistochemistry

1:10-1:500

Immunohistochemistry-Paraffin

1:10-1:500
Application Notes
Succerssful use in ICC/IF, IHC reported in scientific literature (PMID: 22796166).

Reviewed Applications

Read 2 reviews rated 5 using NB100-64021 in the following applications:

Formulation, Preparation, and Storage

Purification

Protein A purified

Formulation

PBS

Preservative

0.09% Sodium Azide

Concentration

1.0 mg/ml

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.

Background: CD8

CD8, also known as Leu-2 or T8 in human and Lyt2 or Lyt3 in mouse, is a cell surface glycoprotein belonging to the immunoglobulin supergene family (1, 2). CD8 is expressed on cytotoxic T-lymphocytes (T-cells), most thymocytes, between 35-45% of peripheral blood lymphocytes, and a population of natural killer (NK) cells (1, 2). The CD8 molecule consists of disulfide-linked alpha (alpha) and beta (beta) chains that present on T-cells as either CD8alphaalpha homodimers or CD8alphabeta heterodimers (1, 3). Both alpha and beta chains consist of a signaling sequence, an extracellular Ig-like domain, a membrane proximal stalk region, a transmembrane domain, and a cytoplasmic tail (3). Human CD8alpha is processed as 235 amino acids (aa) in length with a theoretical molecular weight of ~26 kDa, while mouse CD8alpha is 247 aa and has a theoretical molecular weight of 27.5 kDa (4, 5). Functionally, CD8 acts as an antigen coreceptor on cytotoxic T-cells and interacts with the major histocompatibility complex (MHC) class I molecules on antigen presenting cells (APCs), mediating cell-cell interactions within the immune system. Conversely, CD4 molecules interact with antigens presented on MHC class II molecules and are activated to become helper T-cells (TH) (1,2). Interestingly, thymocytes can transiently express both CD4 and CD8 during the maturation process (2). Furthermore, the cytoplasmic tail of CD8 has a Lck (lymphocyte-specific protein tyrosine kinase) binding domain where Lck interacts with CD8, initiating a phosphorylation cascade that activates transcription factors and promotes T-cell activation (6). More specifically, CD8alphabeta functions as a T-cell co-receptor, while CD8alphaalpha promotes T-cell survival and differentiation (7).

Given its role in the immune system, CD8-deficiency in T-cells is a hallmark of many diseases and pathologies (8-10). Specifically, CD8+ T-cell deficiency is prevalent in chronic autoimmune diseases including multiple sclerosis, rheumatoid arthritis, ulcerative colitis, Crohn's disease, type 1 diabetes mellitus, and Graves' disease (8). Furthermore, cancers or chronic infection can lead to CD8 T-cell exhaustion as the continual antigen presentation and inflammatory signals eventually cause the CD8+ T-cells to lose functionality (9, 10). However, animal models and clinical studies have suggested that T-cells are capable of being reinvigorated using inhibitory receptor blockade resulting in better disease outcomes and these exhausted T-cells may be a potential therapeutic target (9, 10).

Alternative names for CD8 includes CD antigen: CD8a, CD8 antigen, alpha polypeptide (p32), CD8a molecule, CD8A, Leu2 T-lymphocyte antigen, LEU2, MAL, OKT8 T-cell antigen, p32, T cell co-receptor, T8 T-cell antigen, T-cell antigen Leu2, T-cell surface glycoprotein CD8 alpha chain, and T-lymphocyte differentiation antigen T8/Leu-2.

References

1. Littman D. R. (1987). The structure of the CD4 and CD8 genes. Annual review of immunology. https://doi.org/10.1146/annurev.iy.05.040187.003021

2. Naeim F. (2008). Chapter 2- Principles of Immunophenotyping. Hematopathology. https://doi.org/10.1016/B978-0-12-370607-2.00002-8.

3. Gao, G. F., & Jakobsen, B. K. (2000). Molecular interactions of coreceptor CD8 and MHC class I: the molecular basis for functional coordination with the T-cell receptor. Immunology today. https://doi.org/10.1016/s0167-5699(00)01750-3

4. UniProt (P01732)

5. UniProt (P01731)

6. Kappes D. J. (2007). CD4 and CD8: hogging all the Lck. Immunity. https://doi.org/10.1016/j.immuni.2007.11.002

7. Gangadharan, D., & Cheroutre, H. (2004). The CD8 isoform CD8alphaalpha is not a functional homologue of the TCR co-receptor CD8alphabeta. Current opinion in immunology. https://doi.org/10.1016/j.coi.2004.03.015

8. Pender M. P. (2012). CD8+ T-Cell Deficiency, Epstein-Barr Virus Infection, Vitamin D Deficiency, and Steps to Autoimmunity: A Unifying Hypothesis. Autoimmune diseases. https://doi.org/10.1155/2012/189096

9. Kurachi M. (2019). CD8+ T cell exhaustion. Seminars in immunopathology. https://doi.org/10.1007/s00281-019-00744-5

10. Hashimoto, M., Kamphorst, A. O., Im, S. J., Kissick, H. T., Pillai, R. N., Ramalingam, S. S., Araki, K., & Ahmed, R. (2018). CD8 T Cell Exhaustion in Chronic Infection and Cancer: Opportunities for Interventions. Annual review of medicine. https://doi.org/10.1146/annurev-med-012017-043208

Alternate Names

CD8, CD8A

Gene Symbol

CD8A

Additional CD8 Products

Product Documents for CD8 Antibody (12.C7)

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Download SDS

Product Specific Notices for CD8 Antibody (12.C7)

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.